H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Cortexyme (CRTX – Research Report) today and set a price target of $15.00. The company's shares closed last Tuesday at $4.60, close to its 52-week low of $3.79. According to TipRanks.com, Fein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.3% and a 31.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cortexyme with a $13.50 average price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-cortexymes-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Quince Therapeutics Charts.
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Quince Therapeutics Charts.